Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence

PURPOSE: We developed an unbiased framework to study the association of several mutations in predicting resistance to hypomethylating agents (HMAs) in patients with myelodysplastic syndromes (MDS), analogous to consumer and commercial recommender systems in which customers who bought products A and...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JCO Precis Oncol
Autors principals: Nazha, Aziz, Sekeres, Mikkael A., Bejar, Rafael, Rauh, Michael J., Othus, Megan, Komrokji, Rami S., Barnard, John, Hilton, Cameron B., Kerr, Cassandra M., Steensma, David P., DeZern, Amy, Roboz, Gail, Garcia-Manero, Guillermo, Erba, Harry, Ebert, Benjamin L., Maciejewski, Jaroslaw P.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2019
Matèries:
Original Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6818517/
https://ncbi.nlm.nih.gov/pubmed/31663066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.19.00119
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars